Indications and uses
for relief of occasional constipation(irregularity) this product generally produces bowel movement in 6 to 12 hours
for relief of occasional constipation(irregularity) this product generally produces bowel movement in 6 to 12 hours
store between 20° to 25°C (68° to 77° F) protection from excessive humidity
Drug Facts
Bisacodyl 5 mg
Stimulant laxative
Do not use if you cannot swallow without chewing
Ask a doctor before use if you have
When using this product
Stop use and ask doctor if
If pregana or breast-feeding, ask a health professional before use
Keep out of reach of children.In case of overdose,get medical help or contact a poison control center right away.
take with a glass of water
| adults and children 12 years of age and older | - take 1 to 3 tablets in a single dose once daily |
| children 6 to under 12 years of age | - take 1 tablet once daily |
| children under 6 years of age | - ask a doctor |
lactose,cornstarch,povidone (K-30),sodium startch glycolate,talc,magnesium stearate,methacrylic acid copolymer,polethylene glaycol,sodium hydroxide pellets, sucrose,acacia,gelatin,methylparaben, propylparaben, calcium sulphate dihydrate,titanium dioxide,D&C yellow #6 lake, FD & C yellow #10; pharmaceuticals glaze
Y LAX TABLETS DR, 5 mg-SUGAR COATED: YELLOW
Each Delayed Release Tablet Contains
(Bisacodyl 5 mg Tablets,USP)
LOT NO :
DRUM NO :
MFG. DATE :
QUANTITY : 50000
NDC NO : 68210-0001-5
EXP. DATE :
WARNING :
KEEP OUT OF THE REACH OF CHILDREN
STORE CONTROLLED ROOM TEMPRATURE OF 59° – 86°F (15° – 30°C)
PROTECT FROM LIGHT, MOISTURE AND FREEZING
THIS IS A BULK SHIPMENT INTENDED FOR FURTHER PROCESSING ONLY.
CONTENTS SHOULD BE APPROVED,REPACKAGED IMMEDIATELY AND LABELED IN STRICT
CONFORMANCE WITH THE F.D & C.ACT AND REGULATIONS THEREUNDER
MANUFACTURED BY:
LABELLER CODE : 50654
LIC NO. : 25/5/2009
MANUFACTURED FOR:
SPIRIT PHARMACEUTICALS LLC
225 LINCOLN HWY, STE 205
FAIRLESS HILLS , PA 19030
PH.# 215 943 4000, FAX.#215 943 4039
CAUTION : "FOR MANUFACTURING, PROCESSING OR REPACKING"

| Class | Version | Type | Effective |
|---|---|---|---|
| BISACODYL Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20101101 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 89dac932-b90a-4410-9ab1-84c53e57de25 | Product name | 1 | 20150316 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68210-0001-2 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-df80-621f-e053-dbdaa90a74ad | Y LAX TABLETS DR, 5 mg-SUGAR COATED: YELLOW |
| 68210-0001-3 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-df80-621f-e053-dbdaa90a74ad | Y LAX TABLETS DR, 5 mg-SUGAR COATED: YELLOW |
| 68210-0001-4 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-df80-621f-e053-dbdaa90a74ad | Y LAX TABLETS DR, 5 mg-SUGAR COATED: YELLOW |
| 68210-0001-5 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-df80-621f-e053-dbdaa90a74ad | Y LAX TABLETS DR, 5 mg-SUGAR COATED: YELLOW |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68210-0001-2 | Y LAX DR | 250000 in 1 BAG | TABLET, SUGAR COATED | 250000 | 1 | |
| 68210-0001-2 | Y LAX DR | 1 in 1 DRUM | TABLET, SUGAR COATED | 1 | 1 | |
| 68210-0001-3 | Y LAX DR | 300000 in 1 BAG | TABLET, SUGAR COATED | 300000 | 1 | |
| 68210-0001-3 | Y LAX DR | 1 in 1 DRUM | TABLET, SUGAR COATED | 1 | 1 | |
| 68210-0001-4 | Y LAX DR | 1 in 1 DRUM | TABLET, SUGAR COATED | 1 | 1 | |
| 68210-0001-4 | Y LAX DR | 350000 in 1 BAG | TABLET, SUGAR COATED | 350000 | 1 | |
| 68210-0001-5 | Y LAX DR | 1 in 1 DRUM | TABLET, SUGAR COATED | 1 | 1 | |
| 68210-0001-5 | Y LAX DR | 50000 in 1 BAG | TABLET, SUGAR COATED | 50000 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68210-0001 | Y LAX DR (BISACODYL) TABLET, SUGAR COATED [SPIRIT PHARMACEUTICALS,LLC] | 1 | Legacy NDC, 8 package rows | 20100501_eed05b38-4133-44c4-9b3e-81a04555a218.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BISACODYL | ACTIVE INGREDIENT | 10X0709Y6I | 1 | |
| BISACODYL | ACTIVE MOIETY | 10X0709Y6I | 1 | |
| ACACIA | INACTIVE INGREDIENT | 5C5403N26O | 1 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| FD&C YELLOW NO. 6 | INACTIVE INGREDIENT | H77VEI93A8 | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| POLYETHYLENE GLYCOL | INACTIVE INGREDIENT | 3WJQ0SDW1A | 1 | |
| POVIDONE K30 | INACTIVE INGREDIENT | U725QWY32X | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68210-0001 | 68210-0001-5, 68210-0001-2, 68210-0001-3, 68210-0001-4 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BISACODYL | 10X0709Y6I | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| POVIDONE K30 | U725QWY32X | IACT |
| TALC | 7SEV7J4R1U | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| POLYETHYLENE GLYCOL | 3WJQ0SDW1A | IACT |
| SUCROSE | C151H8M554 | IACT |
| ACACIA | 5C5403N26O | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| FD&C YELLOW NO. 6 | H77VEI93A8 | IACT |
| ALUMINUM OXIDE | LMI26O6933 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, DELAYED RELEASE / ORAL | 0.02 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION, CONCENTRATE / ORAL | 1 mg/1ml | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | TABLET, COATED / ORAL | 3.17 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | FILM / SUBLINGUAL | 0.03 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | ELIXIR / ORAL | 5.4 mg/5ml | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 21 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | DROPS / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER, FOR SUSPENSION / ORAL | 735 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET / ORAL | 2828 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| ACACIA | ACACIA | 5C5403N26O | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER / TOPICAL | 9235 mg | ||
| TALC | TALC | 7SEV7J4R1U | ELIXIR / ORAL | 4.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAMUSCULAR | 45 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM / BUCCAL | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SUSPENSION / ORAL | 148 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, COATED PELLETS / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAVENOUS | 95 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, DELAYED RELEASE PARTICLES / ORAL | 70 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SUSPENSION / OPHTHALMIC | 14 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, SUGAR COATED / ORAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, CHEWABLE / ORAL | 180 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GEL / TOPICAL | 24 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | INJECTION / INTRAMUSCULAR | 0.59 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / AURICULAR (OTIC) | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRALESIONAL | 0.15 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | FILM, EXTENDED RELEASE / TRANSDERMAL | 16 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IONTOPHORESIS | 0.1 %w/v | ||
| ALUMINUM OXIDE | ALUMINUM OXIDE | LMI26O6933 | SPONGE / TOPICAL | NA | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, EXTENDED RELEASE / ORAL | 4.59 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | LOTION / TOPICAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SOLUTION / ORAL | 126 mg | ||
| TALC | TALC | 7SEV7J4R1U | LOZENGE / ORAL | 50 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 20 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | GEL / TOPICAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| bc82778e-46c6-4bc3-86f8-c6209faeb8bf | eed05b38-4133-44c4-9b3e-81a04555a218 | 2010-04-21 | Warnings | bc82778e-46c6-4bc3-86f8-c6209faeb8bf eed05b38-4133-44c4-9b3e-81a04555a218 |
Adverse event summaries are temporarily unavailable. Other product information remains available.